
|Articles|June 6, 2019
Syneos Health Consulting Releases Biopharma Dealmakers Survey
Advertisement
Syneos Health Consulting, a biopharmaceutical management consulting firm, released its 11th annual Dealmakers’ Intentions Study. The study indicates there will be an acceleration in dealmaking across all deal types and that buyers seem more willing to accept risk associated with opportunities in the early development and rare disease categories.
To view the study, visit
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Trump Administration’s Leadership Carousel Across Key Agencies
2
FDA Approves Foundayo Under National Priority Voucher Program
3
The New Antitrust Era: Why CVS-Style Healthcare Integration is Now the FTC’s Primary Target
4
President Trump Imposes 100% Tariffs on Branded Pharmaceuticals
5




